Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay J Mathew

Showing results (151-160 of 190) with videos related to

Pageof 19
Sort By:
Brain Research|August 18, 2010
Early-life stress and neurometabolites of the hippocampusJeremy D Coplan, Sanjay J Mathew, Chadi G Abdallah, et al.
Depression and Anxiety|January 1, 2019
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depressionNaji C Salloum, Maurizio Fava, Marlene P Freeman, et al.
The Journal of Clinical Psychiatry|November 16, 2022
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine StudyAnna Feeney, Bettina B Hoeppner, Marlene P Freeman, et al.
Physiology & Behavior|April 5, 2011
Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeysJeremy D Coplan, Chadi G Abdallah, Sanjay J Mathew, et al.
The Journal of Clinical Psychiatry|September 3, 2025
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D TrialKristina T Kumpf, Samuel T Wilkinson, Bo Hu, et al.
Nature Reviews. Drug Discovery|December 29, 2018
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug developmentAndrew D Krystal, Diego A Pizzagalli, Sanjay J Mathew, et al.
Trials|June 22, 2014
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialBoadie W Dunlop, Barbara O Rothbaum, Elisabeth B Binder, et al.
Frontiers in Behavioral Neuroscience|January 8, 2015
Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disordersJeremy D Coplan, Sasha L Fulton, Wade Reiner, et al.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 17, 2020
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Pageof 19

Showing results (151-160 of 190) with videos related to

Sort By:
Pageof 19
Brain Research|August 18, 2010
Early-life stress and neurometabolites of the hippocampusJeremy D Coplan, Sanjay J Mathew, Chadi G Abdallah, et al.
Depression and Anxiety|January 1, 2019
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depressionNaji C Salloum, Maurizio Fava, Marlene P Freeman, et al.
The Journal of Clinical Psychiatry|November 16, 2022
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine StudyAnna Feeney, Bettina B Hoeppner, Marlene P Freeman, et al.
Physiology & Behavior|April 5, 2011
Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeysJeremy D Coplan, Chadi G Abdallah, Sanjay J Mathew, et al.
The Journal of Clinical Psychiatry|September 3, 2025
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D TrialKristina T Kumpf, Samuel T Wilkinson, Bo Hu, et al.
Nature Reviews. Drug Discovery|December 29, 2018
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug developmentAndrew D Krystal, Diego A Pizzagalli, Sanjay J Mathew, et al.
Trials|June 22, 2014
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialBoadie W Dunlop, Barbara O Rothbaum, Elisabeth B Binder, et al.
Frontiers in Behavioral Neuroscience|January 8, 2015
Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disordersJeremy D Coplan, Sasha L Fulton, Wade Reiner, et al.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 17, 2020
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Pageof 19